The stock of Cogent Biosciences Inc (COGT) has seen a -0.28% decrease in the past week, with a 32.72% gain in the past month, and a 20.53% flourish in the past quarter. The volatility ratio for the week is 5.28%, and the volatility levels for the past 30 days are at 7.81% for COGT. The simple moving average for the last 20 days is 3.08% for COGT’s stock, with a simple moving average of -9.69% for the last 200 days.
Is It Worth Investing in Cogent Biosciences Inc (NASDAQ: COGT) Right Now?
Company’s 36-month beta value is 1.88.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for COGT is 94.03M, and currently, short sellers hold a 17.57% ratio of that floaft. The average trading volume of COGT on July 02, 2025 was 1.76M shares.
COGT) stock’s latest price update
Cogent Biosciences Inc (NASDAQ: COGT)’s stock price has gone rise by 0.56 in comparison to its previous close of 7.18, however, the company has experienced a -0.28% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT results in July WALTHAM, Mass. and BOULDER, Colo.
Analysts’ Opinion of COGT
Many brokerage firms have already submitted their reports for COGT stocks, with Scotiabank repeating the rating for COGT by listing it as a “Sector Outperform.” The predicted price for COGT in the upcoming period, according to Scotiabank is $17 based on the research report published on March 07, 2025 of the current year 2025.
Robert W. Baird gave a rating of “Neutral” to COGT, setting the target price at $8 in the report published on February 26th of the previous year.
COGT Trading at 24.58% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.74% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COGT starting from Pinnow Cole, who purchase 43,750 shares at the price of $7.60 back on Jan 14 ’25. After this action, Pinnow Cole now owns 45,848 shares of Cogent Biosciences Inc, valued at $332,412 using the latest closing price.
Stock Fundamentals for COGT
The total capital return value is set at -1.23. Equity return is now at value -84.04, with -70.93 for asset returns.
Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -12.98.
Currently, EBITDA for the company is -275.94 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.13.
Conclusion
In a nutshell, Cogent Biosciences Inc (COGT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
